Literature DB >> 19653786

Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics.

Sharon L Walsh1, William W Stoops, David E Moody, Shen-Nan Lin, George E Bigelow.   

Abstract

Cocaine withdrawal symptoms are thought to play a role in relapse; studies characterizing the symptomatology have yielded mixed findings. This study sought to examine the pharmacodynamic/pharmacokinetic profile of repeated high dose exposure to oral cocaine and characterize acute and protracted withdrawal in cocaine abusers. This study employed a repeated-dosing, single-blind design in which subjects (n = 9), resided for 40 days on a closed ward. They were maintained for two 4-day cocaine exposure periods (Days 1-4 & Days 9-12, cocaine 175 mg, p.o.; 5 hourly doses; 875 mg/day) separated by a 4-day matched placebo exposure period (Days 5-8). After these 12 days, an additional period of 28 days of placebo maintenance followed (Days 13-40). Test sessions were conducted during each phase; measures of mood, drug effects, sleep, pharmacokinetics, and prolactin were collected throughout the study. The dosing regimen produced cocaine plasma concentrations (Cmax of 680 ng/mL) two to threefold higher than typically seen in acute dose studies. Prototypic psychostimulant effects, including subjective ratings of euphoric effects (liking, high, good effects) and significant cardiopressor effects, were sustained during the active dosing periods, corresponding to the rise and fall of plasma cocaine. Withdrawal-like symptoms (i.e., disruptions of sleep, increased ratings of anxiety, irritability, crashing) were observed within 24-hr after cessation of dosing. Cocaine reduced prolactin acutely, but no sustained alterations were observed for this measure or for other signs or symptoms during the 28-day abstinence period. These findings indicate that exposure to controlled high doses of cocaine produces modest symptoms consistent with cocaine withdrawal within hours of cessation of dosing but provide no evidence of symptoms persisting beyond 24 hours. 2009 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653786      PMCID: PMC2811070          DOI: 10.1037/a0016469

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  43 in total

1.  Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration.

Authors:  Amanda J Jenkins; Robert M Keenan; Jack E Henningfield; Edward J Cone
Journal:  J Anal Toxicol       Date:  2002-10       Impact factor: 3.367

2.  Oral cocaine: plasma concentrations and central effects.

Authors:  C Van Dyke; P Jatlow; J Ungerer; P G Barash; R Byck
Journal:  Science       Date:  1978-04-14       Impact factor: 47.728

3.  Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans.

Authors:  Scott H Kollins; Craig R Rush
Journal:  Biol Psychiatry       Date:  2002-01-15       Impact factor: 13.382

4.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.

Authors:  W R Martin; J W Sloan; J D Sapira; D R Jasinski
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

5.  A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma.

Authors:  S N Lin; D E Moody; G E Bigelow; R L Foltz
Journal:  J Anal Toxicol       Date:  2001-10       Impact factor: 3.367

6.  The St. Mary's Hospital sleep questionnaire: a study of reliability.

Authors:  B W Ellis; M W Johns; R Lancaster; P Raptopoulos; N Angelopoulos; R G Priest
Journal:  Sleep       Date:  1981       Impact factor: 5.849

7.  Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans.

Authors:  B J Smith; H E Jones; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2001-08       Impact factor: 4.530

8.  Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence.

Authors:  Kyle M Kampman; Joseph R Volpicelli; Frank Mulvaney; Margaret Rukstalis; Arthur I Alterman; Helen Pettinati; Robert M Weinrieb; Charles P O'Brien
Journal:  Addict Behav       Date:  2002 Mar-Apr       Impact factor: 3.913

9.  Intranasal and oral cocaine kinetics.

Authors:  P Wilkinson; C Van Dyke; P Jatlow; P Barash; R Byck
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

10.  Acute cocaine responses following cocaethylene infusion.

Authors:  Jennifer Baker; Peter Jatlow; Patricia Pade; Viswanathan Ramakrishnan; Elinore F McCance-Katz
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

View more
  17 in total

1.  Exposure of adolescent mice to 3,4-methylenedioxypyrovalerone increases the psychostimulant, rewarding and reinforcing effects of cocaine in adulthood.

Authors:  R López-Arnau; M A Luján; L Duart-Castells; D Pubill; J Camarasa; O Valverde; E Escubedo
Journal:  Br J Pharmacol       Date:  2017-04-06       Impact factor: 8.739

Review 2.  Cocaine hydrolase gene therapy for cocaine abuse.

Authors:  Stephen Brimijoin; Yang Gao
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

3.  Acute withdrawal-related hypophagia elicited by amphetamine is attenuated by pretreatment with selective dopamine D1 or D2 receptor antagonists in rats.

Authors:  Wesley White; Jason D Beyer; Ilsun M White
Journal:  Physiol Behav       Date:  2015-08-07

Review 4.  Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Pharmacol Biochem Behav       Date:  2017-04-22       Impact factor: 3.533

5.  The concept of pharmacologic cocaine interception as a treatment for drug abuse.

Authors:  Yang Gao; Frank M Orson; Berma Kinsey; Tom Kosten; Stephen Brimijoin
Journal:  Chem Biol Interact       Date:  2010-02-26       Impact factor: 5.192

6.  Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.

Authors:  Marion A Coe; Rebecca A Jufer Phipps; Edward J Cone; Sharon L Walsh
Journal:  J Anal Toxicol       Date:  2018-06-01       Impact factor: 3.367

7.  The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment.

Authors:  Robrina Walker; Thomas F Northrup; John Tillitski; Ira Bernstein; Tracy L Greer; Madhukar H Trivedi
Journal:  Subst Use Misuse       Date:  2019-01-18       Impact factor: 2.164

8.  Abstinence-related changes in sleep during treatment for cocaine dependence.

Authors:  G A Angarita; S V Canavan; E Forselius; A Bessette; B Pittman; P T Morgan
Journal:  Drug Alcohol Depend       Date:  2013-11-17       Impact factor: 4.492

Review 9.  Vaccines against stimulants: cocaine and MA.

Authors:  Thomas Kosten; Coreen Domingo; Frank Orson; Berma Kinsey
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

10.  Hyperactivation of the cognitive control network in cocaine use disorders during a multisensory Stroop task.

Authors:  Andrew R Mayer; Claire E Wilcox; Terri M Teshiba; Josef M Ling; Zhen Yang
Journal:  Drug Alcohol Depend       Date:  2013-06-02       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.